Research Article
Bacitracin for Injection Recall: Impact on Immediate Breast Implant Surgical Outcomes
| | | Total (n = 254) | Pre-recall (n = 172) | Post-recall (n = 82) | value |
| | Surgery type | | Augmentation | 17 (6.69) | 10 (5.81) | 7 (8.54) | 0.417 | | Cancer reconstruction | 237 (93.31) | 162 (94.19) | 75 (91.46) | | | Surgical time | 130.11 ± 66.19 | 122.71 ± 66.57 | 145.84 ± 62.95 | 0.009 | | Implant volume | 448.19 ± 143.16 | 452.41 ± 140.80 | 439.32 ± 148.48 | 0.497 | | Use of acellular dermal matrix | 141 (55.51) | 89 (51.74) | 52 (63.41) | 0.080 | | Implant surgical plane | | Pre-pectoral | 231 (90.94) | 157 (91.28) | 74 (90.24) | 0.788 | | Retro-pectoral | 23 (9.06) | 15 (8.72) | 8 (9.76) | | | Irrigation solution | | 0.9% Normal saline | 252 (99.21) | 170 (98.84) | 82 (100.00) | 0.327 | | Lactated Ringer’s | 2 (0.79) | 2 (1.16) | 0 (0.00) | | | Number of antibiotic additives | | 1 | 11 (4.33) | 5 (2.91) | 6 (7.32) | <0.001 | | 2 | 92 (36.22) | 24 (13.95) | 68 (82.93) | | | 3 | 151 (59.45) | 143 (83.14) | 8 (9.76) | | | Antibiotics used | | Bacitracin | 172 (67.72) | 172 (100.00) | 0 (0.00) | <0.001 | | Cefazolin | 212 (83.46) | 142 (82.56) | 70 (85.37) | 0.573 | | Gentamycin | 245 (96.46) | 165 (95.93) | 80 (97) | 0.511 | | Vancomycin | 8 (3.15) | 2 (1.16) | 6 (7.32) | 0.009 | | Polymyxin B | 10 (3.94) | 0 (0.00) | 10 (12.20) | <0.001 | | Povidone-iodine 10% | 216 (85.04) | 144 (83.72) | 72 (87.80) | 0.394 |
|
|
Bold values indicate statistical significance.
|
